University of California, Los Angeles (UCLA), Health Sciences

ACTG Adds New Agent to ACTIV-2 Trial Investigating Early COVID-19 Treatments

Phase 2 Study of BRII-196 and BRII-198 Will Evaluate Combination Monoclonal Antibody Treatment

Newswise — Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the largest global HIV research   network, today announced the addition of a new agent to the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. This phase 2 study, which is being led by the ACTG, will evaluate the combination of the two monoclonal antibodies BRII-196 and BRII-198 to treat early COVID-19. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple promising investigational agents for treating early, symptomatic COVID-19 in a single trial. For information about enrolling in the trial, please visit the study website

BRII-196 and BRII-198 (developed by Brii Biosciences) were derived from antibodies made by people who had recovered from COVID-19. Because BRII-196 and BRII-198 target two different parts of SARS-CoV-2 (the virus that causes COVID-19), the hope is that the combination therapy will improve treatment efficacy and reduce the likelihood that the virus will develop resistance to the treatment. 

“We are excited to add BRII-196 and BRII-198 to ACTIV-2 and to investigate combination monoclonal antibody treatment,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles (UCLA). “While we are thrilled that vaccines to prevent COVID-19 are becoming available, we will continue to need treatments for those who develop COVID-19. Our goal is to increase our understanding of the best ways to treat early COVID-19.”

Participants will be randomized to receive either BRII-196 and BRII-198 (1000 mg each, administered as two separate infusions as a one-time dose) or placebo. As in all ACTIV-2 phase 2 studies, BRII-196 and BRII-198 will be evaluated to determine safety, antiviral activity, and ability to reduce the duration of COVID-19 symptoms over 28 days. Researchers will also assess the correlation between changes in viral shedding and clinical outcomes, leading to a better understanding of whether effective medications can reduce or halt the transmission of SARS-CoV-2 to others. 

ACTIV-2 has progressed on an unprecedented timeline. The ACTG received approval to develop an adaptive master platform trial for outpatients in May 2020 and enrolled the first participant less than 15 weeks later. Following intensive efforts to set up outpatient treatment sites, there are now 88 active U.S. sites, which are enrolling briskly. Thus far, ACTIV-2 has completed a phase 2 study of bamlanivimab (also a monoclonal antibody) and is evaluating several additional agents for potential inclusion (infusions, intramuscular injections, inhaled agents, and oral agents). 

ACTIV-2 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), which also funds the ACTG. ACTIV-2 is part of NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of the most promising treatments and vaccines. It is also receiving support from Operation Warp Speed, the U.S. government’s multi-agency effort to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. 

To qualify for ACTIV-2, participants must have tested positive for SARS-CoV-2 in the outpatient setting and started experiencing symptoms within 10 days of enrolling. All participants eligible to participate in the study of BRII-196 and BRII-198 will have a risk factor that puts them at higher risk of progressing to severe COVID-19, including being age 60 or older, being a current smoker, or having one of the following conditions: chronic lung, kidney, or liver disease; obesity; hypertension; cardiovascular disease; diabetes; or current cancer or immunosuppression. 

The ACTG is committed to enrolling individuals most impacted by COVID-19. To date, nearly a third of ACTIV-2 participants have been Latinx and the ACTG has launched initiatives to increase inclusion of people of color, including establishing research sites in locations where Black, Latinx, Asian, and Native American individuals receive care. 

The study of BRII-196 and BRII-198 is led by Eric S. Daar, M.D., Lundquist Institute at Harbor-UCLA Medical Center and Teresa H. Evering, M.D., M.S., Weill Cornell Medicine. ACTIV-2 is led by Kara W. Chew, M.D., M.S., UCLA and Davey Smith, M.D., University of California, San Diego (protocol chairs) and supported by Dr. Currier and ACTG Co-Chair Joseph J. Eron, M.D., University of North Carolina. 

“COVID-19 continues to have a devastating effect on people around the world,” said Dr. Daar. “It has especially impacted communities of color, who are disproportionately acquiring, being hospitalized with, and dying from COVID-19. We are doing everything in our power to enroll participants from these communities to ensure that the treatments are safe and effective for the populations most impacted by the disease.” 

ACTIV-2 is a randomized, blinded, controlled adaptive platform that allows promising investigational agents to be added and removed over the course of the study, in order to efficiently test a variety of new agents against placebo within the same trial infrastructure. For more information about ACTIV-2, please visit the study website or www.actgnetwork.org.

 

About the ACTG

Founded in 1987, the AIDS Clinical Trials Group (ACTG) was the world’s first HIV research network. The ACTG conducts groundbreaking studies to improve the treatment of HIV and its complications, including tuberculosis and viral hepatitis; reduce new infections and HIV-related illness; and advance new approaches to prevent, treat, and ultimately cure HIV in adults and children. ACTG investigators and research units in 15 countries serve as major resources for HIV/AIDS research, treatment, care, and training/education in their communities. ACTG studies have helped establish current paradigms for managing HIV disease, and have informed HIV treatment guidelines, resulting in dramatic decreases in HIV-related mortality worldwide

 

 




Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.


Showing results

110 of 4573

close
1.19341